| Assessment Status | Rapid Review Complete |
| HTA ID | 24009 |
| Drug | Nivolumab+relatlimab |
| Brand | Opdualag® |
| Indication | Nivolumab+relatlimab (Opdualag® ) is indicated for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%. |
| Assessment Process | |
| Rapid review commissioned | 05/03/2024 |
| Rapid review completed | 16/04/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab+relatlimab compared with the current standard of care. |
